Elevated plasma CD105 and vitreous VEGF levels in diabetic retinopathy

Rayaz Malik, C. Li, W. Aziz, J. A. Olson, A. Vohra, K. C. McHardy, J. V. Forrester, A. J M Boulton, P. B. Wilson, D. Liu, D. McLeod, S. Kumar

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Diabetic retinopathy is the leading cause of blindness in the industrialized world. Hyperglycaemia induces retinal hypoxia that upregulates a range of vasoactive factors which may lead to macular oedema and/or angiogenesis and hence potentially sight threatening retinopathy. In this study, we have focused on the association of CD 105 and vascular endothelial growth factor (VEGF) with the development and progression of diabetic retinopathy by means of quantifying their expression in the plasma and vitreous of diabetic patients. CD105 levels were quantified in the plasma of 38 type I diabetic patients at various stages of retinopathy and 15 non-diabetic controls. In an additional cohort of 11 patients with advanced proliferative retinopathy and 23 control subjects, CD 105 and VEGF were measured in the vitreous. The values were expressed as median (range) and statistical analysis was carried out using the non-parametric Mann-Whitney U test. Plasma CD105 levels were significantly increased in diabetic patients [1.8 (1.1-2.4) ng/ml] compared with non-diabetic controls [0.7 (0.3-1.8) ng/ml] (p<0.01). Plasma CD105 levels were elevated in diabetic patients with all stages of retinopathy, the highest level was observed in background retinopathy [2.3 (2.1-2.5) ng/ml] followed by proliferative retinopathy [2.1 (0.9-2.8) ng/ml] and advanced proliferative retinopathy [1.4 (0.6-1.8) ng/ml]. Vitreous contents of CD105 did not differ between controls and patients with advanced proliferative retinopathy, but vitreous levels of VEGF were elevated by ∼3-fold in patients with advanced proliferative retinopathy [7.2 (1.90-15.60) ng/ml] compared with the control subjects [1.80 (1.10-2.210)] (p<0.01). These observations indicate that plasma levels of CD105 and vitreous levels of VEGF are associated with diabetic retinopathy, suggesting that CD105 and the angiogenic factor VEGF may play a critical role in the development and progression of diabetic retinopathy. Further studies are required to determine whether circulating CD105 levels could serve as a surrogate marker for early stage retinopathy and for monitoring disease progression.

Original languageEnglish
Pages (from-to)692-697
Number of pages6
JournalJournal of Cellular and Molecular Medicine
Volume9
Issue number3
Publication statusPublished - Jul 2005
Externally publishedYes

Fingerprint

Diabetic Retinopathy
Vascular Endothelial Growth Factor A
Plasmas
Angiogenesis Inducing Agents
Macular Edema
Statistical methods
Blindness
Nonparametric Statistics
Hyperglycemia
Disease Progression
Monitoring
Up-Regulation
Biomarkers

Keywords

  • Angiogenesis
  • CD105
  • Diabetic retinopathy
  • VEGF

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry

Cite this

Malik, R., Li, C., Aziz, W., Olson, J. A., Vohra, A., McHardy, K. C., ... Kumar, S. (2005). Elevated plasma CD105 and vitreous VEGF levels in diabetic retinopathy. Journal of Cellular and Molecular Medicine, 9(3), 692-697.

Elevated plasma CD105 and vitreous VEGF levels in diabetic retinopathy. / Malik, Rayaz; Li, C.; Aziz, W.; Olson, J. A.; Vohra, A.; McHardy, K. C.; Forrester, J. V.; Boulton, A. J M; Wilson, P. B.; Liu, D.; McLeod, D.; Kumar, S.

In: Journal of Cellular and Molecular Medicine, Vol. 9, No. 3, 07.2005, p. 692-697.

Research output: Contribution to journalArticle

Malik, R, Li, C, Aziz, W, Olson, JA, Vohra, A, McHardy, KC, Forrester, JV, Boulton, AJM, Wilson, PB, Liu, D, McLeod, D & Kumar, S 2005, 'Elevated plasma CD105 and vitreous VEGF levels in diabetic retinopathy', Journal of Cellular and Molecular Medicine, vol. 9, no. 3, pp. 692-697.
Malik, Rayaz ; Li, C. ; Aziz, W. ; Olson, J. A. ; Vohra, A. ; McHardy, K. C. ; Forrester, J. V. ; Boulton, A. J M ; Wilson, P. B. ; Liu, D. ; McLeod, D. ; Kumar, S. / Elevated plasma CD105 and vitreous VEGF levels in diabetic retinopathy. In: Journal of Cellular and Molecular Medicine. 2005 ; Vol. 9, No. 3. pp. 692-697.
@article{364c52d2d90040e8abeb543bdb372273,
title = "Elevated plasma CD105 and vitreous VEGF levels in diabetic retinopathy",
abstract = "Diabetic retinopathy is the leading cause of blindness in the industrialized world. Hyperglycaemia induces retinal hypoxia that upregulates a range of vasoactive factors which may lead to macular oedema and/or angiogenesis and hence potentially sight threatening retinopathy. In this study, we have focused on the association of CD 105 and vascular endothelial growth factor (VEGF) with the development and progression of diabetic retinopathy by means of quantifying their expression in the plasma and vitreous of diabetic patients. CD105 levels were quantified in the plasma of 38 type I diabetic patients at various stages of retinopathy and 15 non-diabetic controls. In an additional cohort of 11 patients with advanced proliferative retinopathy and 23 control subjects, CD 105 and VEGF were measured in the vitreous. The values were expressed as median (range) and statistical analysis was carried out using the non-parametric Mann-Whitney U test. Plasma CD105 levels were significantly increased in diabetic patients [1.8 (1.1-2.4) ng/ml] compared with non-diabetic controls [0.7 (0.3-1.8) ng/ml] (p<0.01). Plasma CD105 levels were elevated in diabetic patients with all stages of retinopathy, the highest level was observed in background retinopathy [2.3 (2.1-2.5) ng/ml] followed by proliferative retinopathy [2.1 (0.9-2.8) ng/ml] and advanced proliferative retinopathy [1.4 (0.6-1.8) ng/ml]. Vitreous contents of CD105 did not differ between controls and patients with advanced proliferative retinopathy, but vitreous levels of VEGF were elevated by ∼3-fold in patients with advanced proliferative retinopathy [7.2 (1.90-15.60) ng/ml] compared with the control subjects [1.80 (1.10-2.210)] (p<0.01). These observations indicate that plasma levels of CD105 and vitreous levels of VEGF are associated with diabetic retinopathy, suggesting that CD105 and the angiogenic factor VEGF may play a critical role in the development and progression of diabetic retinopathy. Further studies are required to determine whether circulating CD105 levels could serve as a surrogate marker for early stage retinopathy and for monitoring disease progression.",
keywords = "Angiogenesis, CD105, Diabetic retinopathy, VEGF",
author = "Rayaz Malik and C. Li and W. Aziz and Olson, {J. A.} and A. Vohra and McHardy, {K. C.} and Forrester, {J. V.} and Boulton, {A. J M} and Wilson, {P. B.} and D. Liu and D. McLeod and S. Kumar",
year = "2005",
month = "7",
language = "English",
volume = "9",
pages = "692--697",
journal = "Journal of Cellular and Molecular Medicine",
issn = "1582-1838",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Elevated plasma CD105 and vitreous VEGF levels in diabetic retinopathy

AU - Malik, Rayaz

AU - Li, C.

AU - Aziz, W.

AU - Olson, J. A.

AU - Vohra, A.

AU - McHardy, K. C.

AU - Forrester, J. V.

AU - Boulton, A. J M

AU - Wilson, P. B.

AU - Liu, D.

AU - McLeod, D.

AU - Kumar, S.

PY - 2005/7

Y1 - 2005/7

N2 - Diabetic retinopathy is the leading cause of blindness in the industrialized world. Hyperglycaemia induces retinal hypoxia that upregulates a range of vasoactive factors which may lead to macular oedema and/or angiogenesis and hence potentially sight threatening retinopathy. In this study, we have focused on the association of CD 105 and vascular endothelial growth factor (VEGF) with the development and progression of diabetic retinopathy by means of quantifying their expression in the plasma and vitreous of diabetic patients. CD105 levels were quantified in the plasma of 38 type I diabetic patients at various stages of retinopathy and 15 non-diabetic controls. In an additional cohort of 11 patients with advanced proliferative retinopathy and 23 control subjects, CD 105 and VEGF were measured in the vitreous. The values were expressed as median (range) and statistical analysis was carried out using the non-parametric Mann-Whitney U test. Plasma CD105 levels were significantly increased in diabetic patients [1.8 (1.1-2.4) ng/ml] compared with non-diabetic controls [0.7 (0.3-1.8) ng/ml] (p<0.01). Plasma CD105 levels were elevated in diabetic patients with all stages of retinopathy, the highest level was observed in background retinopathy [2.3 (2.1-2.5) ng/ml] followed by proliferative retinopathy [2.1 (0.9-2.8) ng/ml] and advanced proliferative retinopathy [1.4 (0.6-1.8) ng/ml]. Vitreous contents of CD105 did not differ between controls and patients with advanced proliferative retinopathy, but vitreous levels of VEGF were elevated by ∼3-fold in patients with advanced proliferative retinopathy [7.2 (1.90-15.60) ng/ml] compared with the control subjects [1.80 (1.10-2.210)] (p<0.01). These observations indicate that plasma levels of CD105 and vitreous levels of VEGF are associated with diabetic retinopathy, suggesting that CD105 and the angiogenic factor VEGF may play a critical role in the development and progression of diabetic retinopathy. Further studies are required to determine whether circulating CD105 levels could serve as a surrogate marker for early stage retinopathy and for monitoring disease progression.

AB - Diabetic retinopathy is the leading cause of blindness in the industrialized world. Hyperglycaemia induces retinal hypoxia that upregulates a range of vasoactive factors which may lead to macular oedema and/or angiogenesis and hence potentially sight threatening retinopathy. In this study, we have focused on the association of CD 105 and vascular endothelial growth factor (VEGF) with the development and progression of diabetic retinopathy by means of quantifying their expression in the plasma and vitreous of diabetic patients. CD105 levels were quantified in the plasma of 38 type I diabetic patients at various stages of retinopathy and 15 non-diabetic controls. In an additional cohort of 11 patients with advanced proliferative retinopathy and 23 control subjects, CD 105 and VEGF were measured in the vitreous. The values were expressed as median (range) and statistical analysis was carried out using the non-parametric Mann-Whitney U test. Plasma CD105 levels were significantly increased in diabetic patients [1.8 (1.1-2.4) ng/ml] compared with non-diabetic controls [0.7 (0.3-1.8) ng/ml] (p<0.01). Plasma CD105 levels were elevated in diabetic patients with all stages of retinopathy, the highest level was observed in background retinopathy [2.3 (2.1-2.5) ng/ml] followed by proliferative retinopathy [2.1 (0.9-2.8) ng/ml] and advanced proliferative retinopathy [1.4 (0.6-1.8) ng/ml]. Vitreous contents of CD105 did not differ between controls and patients with advanced proliferative retinopathy, but vitreous levels of VEGF were elevated by ∼3-fold in patients with advanced proliferative retinopathy [7.2 (1.90-15.60) ng/ml] compared with the control subjects [1.80 (1.10-2.210)] (p<0.01). These observations indicate that plasma levels of CD105 and vitreous levels of VEGF are associated with diabetic retinopathy, suggesting that CD105 and the angiogenic factor VEGF may play a critical role in the development and progression of diabetic retinopathy. Further studies are required to determine whether circulating CD105 levels could serve as a surrogate marker for early stage retinopathy and for monitoring disease progression.

KW - Angiogenesis

KW - CD105

KW - Diabetic retinopathy

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=27744514210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744514210&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 692

EP - 697

JO - Journal of Cellular and Molecular Medicine

JF - Journal of Cellular and Molecular Medicine

SN - 1582-1838

IS - 3

ER -